TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21132310

Group type: EXPERIMENTAL
Intervention: Intracoronary pyruvate (300 mmol/L, 360 ml/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care with primary PCI and intra‐aortic balloon pump (IABP)
Number of subjects: 0
Study: 18300256

Group type: EXPERIMENTAL
Intervention: Docetaxel every 3 weeks (75 mg/m2)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Docetaxel weekly (35 mg/m2)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Docetaxel every 3 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Docetaxel weekly
Number of subjects: 118
Study: 16966982

Group type: EXPERIMENTAL
Intervention: Brief counseling
Number of subjects: 187

Group type: COMPARATOR
Intervention: Simple advice
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study: 15115076

Group type: EXPERIMENTAL
Intervention: Dot-ELISA using FG 27 antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control sera from patients with other parasitic infections and healthy volunteers
Number of subjects: 0
Study: 11125778

Group type: EXPERIMENTAL
Intervention: Adolescent Transitions Program (ATP)
Number of subjects: 0
Study: 8807169

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg-1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg-1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms.kg-1
Number of subjects: 80
Study: 1384256

Group type: EXPERIMENTAL
Intervention: MOPP-ABVD (MOPP: Mustine, Vincristine, Procarbazine, Prednisone; ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
Number of subjects: 54

Group type: COMPARATOR
Intervention: MOPP-ABVD-CEM (CEM: Carmustine, Etoposide, methyl-GAG)
Number of subjects: 54
Study: 6532147

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g of ethanol per kg of body weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-alcohol treatments
Number of subjects: 40
Study: 31325144

Group type: EXPERIMENTAL
Intervention: Bevacizumab/Irinotecan (BEV/IRI)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 121
Study: 29806181

Group type: EXPERIMENTAL
Intervention: Connective tissue graft (test group, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No connective tissue graft (control group, n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 26285178

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by misoprostol 800 mcg vaginally 6-8 or 23-25 hours later
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by misoprostol 800 mcg vaginally < 15 min or 23-25 hours later
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Parity of five or more deliveries
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Gestational age of 8 weeks or more
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Age of 20 years or younger
Number of subjects: 2160
Study: 25411292

Group type: EXPERIMENTAL
Intervention: Dietary fat quality (ratio of unsaturated to saturated fats)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dietary lipid quality
Number of subjects: 2
Study: 22987495

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Psychoanalytic therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 100
Study: 21275357

Group type: EXPERIMENTAL
Intervention: Pneumatic leg brace
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard rehabilitation (No brace)
Number of subjects: 15
Study: 16806873

Group type: EXPERIMENTAL
Intervention: Sit-to-Stand Test (STST)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 6 min walk test (6MWT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 6MWT
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: STST and 6MWT
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: STST
Number of subjects: 53
Study: 15653703

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) 4 g/m² followed by leucovorin rescue
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 154
Study: 12040528

Group type: EXPERIMENTAL
Intervention: Rituximab + interferon-α2a
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rituximab + granulocyte-colony stimulating factor
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 20
Study: 9860150

Group type: EXPERIMENTAL
Intervention: L-NAME 1 mg x kg(‐1) x h(‐1) for 12 hours
Number of subjects: 9
Study: 7719244

Group type: EXPERIMENTAL
Intervention: Various biologic and chemotherapeutic agents for hairy-cell leukemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 2692651

Group type: EXPERIMENTAL
Intervention: Weekly 20 mg doses of doxorubicin
Number of subjects: 143
Study: 30168357

Group type: COMPARATOR
Intervention: Inverted pendulum model during level walking in able-bodied participants
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inverted pendulum model during level walking in individuals with unilateral transfemoral amputation
Number of subjects: 25
Study: 29349976

Group type: EXPERIMENTAL
Intervention: Two-week irrigation group
Number of subjects: 23

Group type: COMPARATOR
Intervention: One-week irrigation group
Number of subjects: 23
Study: 25440999

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg orally once a day for 12 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg orally once a day for 12 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison between telmisartan and lisinopril
Number of subjects: 62
Study: 24364174

Group type: EXPERIMENTAL
Intervention: Coronally displaced flap plus amnion allograft
Number of subjects: 22

Group type: COMPARATOR
Intervention: Coronally displaced flap plus connective tissue graft
Number of subjects: 22
Study: 21502541

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19496776

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16500321

Group type: EXPERIMENTAL
Intervention: Cetrorelix (0.25 mg SC) with half dose of recombinant FSH for 2 days until hCG administration
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (n = 32) continued recombinant FSH until hCG administration
Number of subjects: 67
Study: 12795584

Group type: EXPERIMENTAL
Intervention: Behavioral day treatment plus abstinence-contingent housing and work therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral day treatment only
Number of subjects: 0
Study: 10856892

Group type: EXPERIMENTAL
Intervention: Intravenous TRH administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nasal TRH administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral TRH administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TRH stimulation (30 min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TRH stimulation (60 min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TRH stimulation (180 min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TRH stimulation (120 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Basal TSH
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pituitary standard TSH (IRP 80/558)
Number of subjects: 20
Study: 9168167

Group type: EXPERIMENTAL
Intervention: Clonazepam (1 mg for 1 day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Vigabatrin (1000 mg per day for 5 days)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Clonazepam and Vigabatrin
Number of subjects: 4
Study: 8251283

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80
Study: 3510282

Group type: EXPERIMENTAL
Intervention: Continuous cyclic therapy with dibromodulcitol, doxorubicin, vincristine, tamoxifen, and fluoxymesterone (DAVTH)
Number of subjects: 97

Group type: COMPARATOR
Intervention: DAVTH alternating with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFP)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Low pretreatment CEA levels
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Elevated pretreatment CEA levels
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Serial CEA levels during therapy
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Rising CEA levels
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Patients with unknown ER status
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Continuous DAVTH therapy
Number of subjects: 97
Study: 29807301

Group type: COMPARATOR
Intervention: New pointe shoes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Worn pointe shoes (>20 hours wear)
Number of subjects: 15
Study: 26305603

Group type: EXPERIMENTAL
Intervention: iPad‐delivered multiple behavior tailored intervention (Healthy Pregnancy: Step by Step)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Usual care (March of Dimes brochures)
Number of subjects: 335
Study: 24884602

Group type: EXPERIMENTAL
Intervention: Canakinumab low dose (0.03 mg/kg i.v. once, N = 20)
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Canakinumab intermediate dose (0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly, N = 247)
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Canakinumab medium dose (1.5 mg/kg i.v. once, 50 mg s.c. monthly and 150 mg s.c. once, N = 268)
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Canakinumab high dose (10 mg/kg i.v. once and 150 mg s.c. monthly, N = 137)
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Placebo (N = 354)
Number of subjects: 1026
Study: 23102995

Group type: EXPERIMENTAL
Intervention: Olmesartan plus Calcium Channel Blocker (CCB)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Olmesartan plus Diuretic
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Olmesartan plus CCB
Number of subjects: 58
Study: 20634749

Group type: EXPERIMENTAL
Intervention: Hold Breath (HB) technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controlled Breathing technique
Number of subjects: 30
Study: 18607829

Group type: EXPERIMENTAL
Intervention: sFlt-1:PlGF ratio
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: endoglin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: sFlt-1
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: PlGF
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: sFlt-1:PlGF
Number of subjects: 104
Study: 16080670

Group type: EXPERIMENTAL
Intervention: Radiofrequency sinus excision
Number of subjects: 35

Group type: COMPARATOR
Intervention: Excision and marsupialization
Number of subjects: 35
Study: 12572787

Group type: EXPERIMENTAL
Intervention: Distance education program for diarrhea and cholera case management
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (doctors and nurses not offered the course)
Number of subjects: 132
Study: 10511389

Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (after exclusion of a trial with extreme results)
Number of subjects: 2609
Study: 7772429

Group type: EXPERIMENTAL
Intervention: 0.22% halothane
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no halothane)
Number of subjects: 12
Study: 1828408

Group type: EXPERIMENTAL
Intervention: Esaprazole (450 mg bid)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sulglicotide (200 mg tid)
Number of subjects: 50
Study: 7014284

Group type: EXPERIMENTAL
Intervention: 10 mg i.m. domperidone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10 mg t.i.d. domperidone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31631377

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 1829
Study: 28389389

Group type: EXPERIMENTAL
Intervention: Capsaicin nasal spray
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 26010860

Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg/day for 6 weeks, with dose escalation up to 50mg/day for non-responders
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dietary fatty fish intake
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Initial low FA-chain length, FA-peroxidation, and EPA in early responders
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cortisol and FA measures repeated after 6 and 12 weeks
Number of subjects: 70
Study: 23229087

Group type: EXPERIMENTAL
Intervention: Facing Forward booklet
Number of subjects: 340

Group type: COMPARATOR
Intervention: Attention control booklet about the NCI's Cancer Information Service
Number of subjects: 340
Study: 21300339

Group type: EXPERIMENTAL
Intervention: Depot leuprolide, 11.25 mg IM every 12 weeks with hormonal add-back using norethindrone acetate 5 mg orally, daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Generic monophasic oral contraceptive (1 mg norethindrone + 35 mg ethinyl estradiol) given daily
Number of subjects: 47
Study: 19485822

Group type: EXPERIMENTAL
Intervention: SCTG with a retained epithelial collar + CAF (SCTGE; n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SCTG without an epithelial collar + CAF (SCTGN; n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SCTGE
Number of subjects: 20

Group type: COMPARATOR
Intervention: SCTGN
Number of subjects: 20
Study: 16563078

Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder (BPD) group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Generic item recognition memory
Number of subjects: 41
Study: 15503074

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program (six modules in five weekly group sessions)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison group without intervention
Number of subjects: 22
Study: 11416677

Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 16 mg once daily, increased to 32 mg after 2 weeks
Number of subjects: 654

Group type: COMPARATOR
Intervention: losartan 50 mg once daily, increased to 100 mg after 2 weeks
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: candesartan cilexetil
Number of subjects: 654

Group type: COMPARATOR
Intervention: losartan
Number of subjects: 654
Study: 9293650

Group type: EXPERIMENTAL
Intervention: 30 ml of 0.125% bupivacaine (with 1/200,000 epinephrine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 30 ml of isotonic saline (with 1/200,000 epinephrine)
Number of subjects: 60
Study: 8447520

Group type: EXPERIMENTAL
Intervention: Low clearing doses of ivermectin followed by 200-400 micrograms/kg of ivermectin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 220 micrograms/kg of ivermectin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 6 or 7 mg/kg of DEC
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Clearing dose of ivermectin followed by 6 mg/kg of DEC
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 3768248

Group type: EXPERIMENTAL
Intervention: Theophylline preparation with ethylenediamine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Theophylline preparation with sodium glycinate
Number of subjects: 6
Study: 29696963

Group type: EXPERIMENTAL
Intervention: Metoprolol (on the basis of aspirin)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Aspirin (control group)
Number of subjects: 92
Study: 26796240

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Exercise + Whole-body vibration (EX + WBV)
Number of subjects: 19
Study: 24178976

Group type: EXPERIMENTAL
Intervention: Cockcroft and Gault estimated GFR tertiles
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Modification of Diet in Renal Disease estimated GFR tertiles
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease‐Epidemiology Collaboration estimated GFR tertiles
Number of subjects: 768
Study: 23365129

Group type: EXPERIMENTAL
Intervention: Cinacalcet and low-dose vitamin D sterols (Cin-D)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Larger, varying doses of calcitriol or other vitamin D analogs (Flex-D)
Number of subjects: 304
Study: 20601929

Group type: EXPERIMENTAL
Intervention: Expedited partner therapy (EPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard partner referral (SPR)
Number of subjects: 0
Study: 18664833

Group type: EXPERIMENTAL
Intervention: Automated polyp size measurement tool in computed tomographic colonography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual and endoscopic measurements
Number of subjects: 0
Study: 16422889

Group type: EXPERIMENTAL
Intervention: Testosterone patch (5 mg/day applied at 2200 h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Testosterone gel (5 g/day applied at 0800 h)
Number of subjects: 28
Study: 12835492

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg/d) for 14 weeks followed by copper supplementation (3 mg/d) for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo supplements for the full duration of the trial
Number of subjects: 38
Study: 10805844

Group type: EXPERIMENTAL
Intervention: Absolute ethanol
Number of subjects: 157

Group type: COMPARATOR
Intervention: 5% ethanolamine oleate
Number of subjects: 157
Study: 8873633

Group type: EXPERIMENTAL
Intervention: Pentoxifylline therapy
Number of subjects: 612

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 612
Study: 1387041

Group type: EXPERIMENTAL
Intervention: Oral terfenadine (120 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nasal ipratropium bromide (80 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral terfenadine (120 mg) and nasal ipratropium bromide (80 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 8
Study: 6437102

Group type: EXPERIMENTAL
Intervention: 0.4 mg levonorgestrel per coitus
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.75 mg levonorgestrel per coitus
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both doses of levonorgestrel
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Levonorgestrel for postcoital contraception
Number of subjects: 104
Study: 30266256

Group type: EXPERIMENTAL
Intervention: Traumatic life events
Number of subjects: 24809

Group type: EXPERIMENTAL
Intervention: Financial stress
Number of subjects: 24809

Group type: EXPERIMENTAL
Intervention: Neighborhood stress
Number of subjects: 24809

Group type: EXPERIMENTAL
Intervention: Confirmed AF prevalence
Number of subjects: 24809
Study: 27445627

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 12982

Group type: EXPERIMENTAL
Intervention: Chronic pain severity
Number of subjects: 12982
Study: 24670520

Group type: EXPERIMENTAL
Intervention: rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF)
Number of subjects: 476

Group type: COMPARATOR
Intervention: protease inhibitor+RTV+two NRTIs
Number of subjects: 476
Study: 23158423

Group type: EXPERIMENTAL
Intervention: Group A (35 ml contrast medium)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group B (40 ml contrast medium)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group C (45 ml contrast medium)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group D (50 ml contrast medium)
Number of subjects: 120
Study: 19022318

Group type: EXPERIMENTAL
Intervention: Low-dose intradermal injection (3 microg hemagglutinin per strain) using MicronJet (ID1 group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Medium-dose intradermal injection (6 microg hemagglutinin per strain) using MicronJet (ID2 group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Full-dose standard flu shot (15 microg hemagglutinin per strain) delivered intramuscularly (IM group)
Number of subjects: 180
Study: 17509210

Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol
Number of subjects: 27

Group type: COMPARATOR
Intervention: GnRH agonist protocol
Number of subjects: 27
Study: 16032525

Group type: EXPERIMENTAL
Intervention: Case-cohort study design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full cohort study
Number of subjects: 0
Study: 11927418

Group type: EXPERIMENTAL
Intervention: Conductive keratoplasty (CK)
Number of subjects: 54
Study: 9813675

Group type: EXPERIMENTAL
Intervention: Open reduction and Herbert screw fixation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open reduction and Kirschner wire fixation
Number of subjects: 12
Study: 8088392

Group type: EXPERIMENTAL
Intervention: Chronic electromyostimulation (CEMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcutaneous nerve stimulation (TENS) placebo
Number of subjects: 0
Study: 2574193

Group type: EXPERIMENTAL
Intervention: Diazepam (N = 21; mean diazepam dose equivalents, 15 mg/day; range, 5‐40)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (N = 19)
Number of subjects: 63
Study: 30583913

Group type: EXPERIMENTAL
Intervention: Meducation® eye drop technique video
Number of subjects: 92

Group type: COMPARATOR
Intervention: Nutrition video
Number of subjects: 92
Study: 28665371

Group type: EXPERIMENTAL
Intervention: mexidol: 500 mg/day IV infusion for 10 days, followed by 125 mg tid (375 mg/day) PO for 8 weeks
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: mexidol
Number of subjects: 151

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 151
Study: 24934438

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Labour pain
Number of subjects: 12
Study: 23457387

Group type: COMPARATOR
Intervention: Placebo + Methotrexate (MTX), n = 37
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Golimumab (combined 50 mg + MTX or 100 mg ± MTX), n = 115
Number of subjects: 152
Study: 21930598

Group type: EXPERIMENTAL
Intervention: Prior endurance exercise (∼50 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no prior exercise)
Number of subjects: 10
Study: 19197778

Group type: EXPERIMENTAL
Intervention: Smoking Consequences Questionnaire-Adult (SCQ-A)
Number of subjects: 751
Study: 16786407

Group type: EXPERIMENTAL
Intervention: Victim's emotional response severity (severe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Victim's emotional response severity (mild)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proportionality norm (matching emotional response to crime seriousness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender of the victim
Number of subjects: 0